High CCN3 expression correlates with a poor prognosis in renal and prostate carcinomas, Ewing tumors, osteosarcomas and melanoma, whereas in gliomas, chronic myeloid leukemia, malignant adrenocortical tumors and neuroblastoma, high CCN3 expression is associated with a good prognosis [31, 35]. This evidence concerns the gene CCN3 and chronic myelogenous leukemia, BCR-ABL1 positive.